Left Atrial Appendage Occlusion: Current and Future

Dian Andina munawar; Anggia Chairuddin lubis; Muhammad Munawar

doi:10.5772/intechopen.105776

Left Atrial Appendage Occlusion: Current and Future

Dian Andina munawar, Anggia Chairuddin lubis, Muhammad Munawar

Department of Cardiology and Vascular Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Patients with non-valvular atrial fibrillation (NVAF) are at an increased risk of ischemic stroke due to the risks of thrombus formation. The left atrial appendage (LAA) is shown to be “the culprit” of thromboembolic events in NVAF and is currently a therapeutic target to prevent stroke. The absolute benefit of oral anticoagulation in the management of NVAF to improve cardiovascular outcomes has been well established. However, some patients are not good long-term candidates for oral anticoagulation for many reasons, including risks of bleeding, noncompliant to oral anticoagulation (OAC). Left atrial appendage occlusion (LAAO) provides an attractive alternative to reduce the risk of stroke for those who are contraindicated to OAC therapy.

Original language	English
Title of host publication	Atrial Fibrillation - Diagnosis and Management in the 21st Century
Editors	Özgür Karcıoğlu, Funda Karbek Akarca
Publisher	IntechOpen
Chapter	8
ISBN (Electronic)	978-1-80356-123-3
ISBN (Print)	978-1-80356-122-6
DOIs	https://doi.org/10.5772/intechopen.105776
Publication status	Published - 30 Nov 2022

Keywords

atrial fibrillation
left atrial appendage closure
left atrial appendage device
ischemic stroke
oral anticoagulation

Access to Document

10.5772/intechopen.105776

Cite this

@inbook{361091e1cb2b40f68a801410e0e42a1b,

title = "Left Atrial Appendage Occlusion: Current and Future",

abstract = "Patients with non-valvular atrial fibrillation (NVAF) are at an increased risk of ischemic stroke due to the risks of thrombus formation. The left atrial appendage (LAA) is shown to be “the culprit” of thromboembolic events in NVAF and is currently a therapeutic target to prevent stroke. The absolute benefit of oral anticoagulation in the management of NVAF to improve cardiovascular outcomes has been well established. However, some patients are not good long-term candidates for oral anticoagulation for many reasons, including risks of bleeding, noncompliant to oral anticoagulation (OAC). Left atrial appendage occlusion (LAAO) provides an attractive alternative to reduce the risk of stroke for those who are contraindicated to OAC therapy.",

keywords = "atrial fibrillation, left atrial appendage closure, left atrial appendage device, ischemic stroke, oral anticoagulation",

author = "{Andina munawar}, Dian and {Chairuddin lubis}, Anggia and Muhammad Munawar",

year = "2022",

month = nov,

day = "30",

doi = "10.5772/intechopen.105776",

language = "English",

isbn = "978-1-80356-122-6",

editor = "{\"O}zg{\"u}r Karcıoğlu and {Karbek Akarca}, Funda",

booktitle = "Atrial Fibrillation - Diagnosis and Management in the 21st Century",

publisher = "IntechOpen",

}

TY - CHAP

T1 - Left Atrial Appendage Occlusion: Current and Future

AU - Andina munawar, Dian

AU - Chairuddin lubis, Anggia

AU - Munawar, Muhammad

PY - 2022/11/30

Y1 - 2022/11/30

N2 - Patients with non-valvular atrial fibrillation (NVAF) are at an increased risk of ischemic stroke due to the risks of thrombus formation. The left atrial appendage (LAA) is shown to be “the culprit” of thromboembolic events in NVAF and is currently a therapeutic target to prevent stroke. The absolute benefit of oral anticoagulation in the management of NVAF to improve cardiovascular outcomes has been well established. However, some patients are not good long-term candidates for oral anticoagulation for many reasons, including risks of bleeding, noncompliant to oral anticoagulation (OAC). Left atrial appendage occlusion (LAAO) provides an attractive alternative to reduce the risk of stroke for those who are contraindicated to OAC therapy.

AB - Patients with non-valvular atrial fibrillation (NVAF) are at an increased risk of ischemic stroke due to the risks of thrombus formation. The left atrial appendage (LAA) is shown to be “the culprit” of thromboembolic events in NVAF and is currently a therapeutic target to prevent stroke. The absolute benefit of oral anticoagulation in the management of NVAF to improve cardiovascular outcomes has been well established. However, some patients are not good long-term candidates for oral anticoagulation for many reasons, including risks of bleeding, noncompliant to oral anticoagulation (OAC). Left atrial appendage occlusion (LAAO) provides an attractive alternative to reduce the risk of stroke for those who are contraindicated to OAC therapy.

KW - atrial fibrillation

KW - left atrial appendage closure

KW - left atrial appendage device

KW - ischemic stroke

KW - oral anticoagulation

UR - https://www.intechopen.com/chapters/82910

U2 - 10.5772/intechopen.105776

DO - 10.5772/intechopen.105776

M3 - Chapter

SN - 978-1-80356-122-6

BT - Atrial Fibrillation - Diagnosis and Management in the 21st Century

A2 - Karcıoğlu, Özgür

A2 - Karbek Akarca, Funda

PB - IntechOpen

ER -

Left Atrial Appendage Occlusion: Current and Future

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this